Development of biomarkers to optimize pediatric patient management: What makes children different?

Biomarkers in Medicine

Volumn 5, Issue 6, 2011, Pages 781-794

  Goldman, Jennifer ^a,b   Becker, Mara L ^a,b   Jones, Bridgette ^a,b   Clements, Mark ^a,b   Leeder, J Steven ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; children; development; genomics; ontogeny; pediatrics; pharmacogenomics

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; CHLORPHENIRAMINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DEXTROMETHORPHAN; DIPHENHYDRAMINE; FOLIC ACID; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PLACEBO; PRAVASTATIN; TRAMADOL; WARFARIN;

ALLERGIC RHINITIS; ALLERGY; ANTHROPOMETRIC PARAMETERS; ASTHMA; CHILD CARE; CHILD DEVELOPMENT; CHILD GROWTH; CHILDHOOD DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; ENDOCRINE DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC MARKER; GENETIC VARIABILITY; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; GLOMERULUS FILTRATION RATE; GROWTH CURVE; HUMAN; IMMUNOPATHOLOGY; INTENSIVE CARE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; MEDICAL CARE; MENTAL DISEASE; NON INVASIVE PROCEDURE; ONTOGENY; PATHOGENESIS; PATIENT CARE; PHARMACOGENETICS; REFERENCE VALUE; RELIABILITY; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VALIDITY;

ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CHILD; FOLIC ACID; GENOTYPE; HUMANS; METHOTREXATE; PEDIATRICS; PHARMACOGENETICS; REFERENCE VALUES;

EID: 82755195593     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.96     Document Type: Review

References (87)

1. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 1, 182-188 (2001). (Pubitemid 46589350)
2. Atkinson AJ, Colburn WA, Degruttola VG et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001). (Pubitemid 32225406)
3. Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1(2), 189-195 (2004). (Pubitemid 46604746)
4. Savage WJ, Everett AD. Biomarkers in pediatrics: children as biomarker orphans. Proteomics Clin. Appl. 4(12), 915-921 (2010).
5. Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: a review. Rev. Environ. Health 24(1), 15-45 (2009).
6. Manzano S, Bailey B, Gervaix A, Cousineau J, Delvin E, Girodias JB. Markers for bacterial infection in children with fever without source. Arch. Dis. Child. 96(5), 440-446 (2011).
7. Goldstein DE, Walker B, Rawlings SS et al. Hemoglobin A1c levels in children and adolescents with diabetes mellitus. Diabetes Care 3(4), 503-507 (1980). (Pubitemid 10011608)
8. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology -drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003). (Pubitemid 37122329)
9. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58(2), 259-263 (1976).
10. Skinner AM, Addison GM, Price DA. Changes in the urinary excretion of creatinine, albumin and N-acetyl-beta-d-glucosaminidase with increasing age and maturity in healthy schoolchildren. Eur. J. Pediatr. 155(7), 596-602 (1996). (Pubitemid 26231576)
11. Chevalier RL. Developmental renal physiology of the low birth weight pre-term newborn. J. Urol. 156(2 Pt 2), 714-719 (1996). (Pubitemid 126444910)
12. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr. Nephrol. 21(2), 160-168 (2006). (Pubitemid 43115865)
13. Ceriotti F, Boyd JC, Klein G et al. Reference intervals for serum creatinine concentrations: assessment of available data for global application. Clin. Chem. 54(3), 559-566 (2008). (Pubitemid 351359026)
14. Children Are Different: Developmental Physiology. John TR, Moore W, Jeffries JE (Eds). Ross Laboratories, Columbus, OH, USA (1978).
15. Al-Ismaili Z, Palijan A, Zappitelli M. Biomarkers of acute kidney injury in children: discover, evaluation, and clinical application. Pediatr. Nephrol. 26, 29-40 (2011).
16. Shore GM, Hoberman L, Dowdey BC, Combes B. Serum gamma-glutamyl transpeptidase activity in normal children. Am. J. Clin. Pathol. 63(2), 245-250 (1975).
17. Yip R, Johnson C, Dallman PR. Age-related changes in laboratory values used in the diagnosis of anemia and iron deficiency. Am. J. Clin. Nutr. 39(3), 427-436 (1984). (Pubitemid 14154629)
18. England K, Thorne C, Pembrey L, Tovo PA, Newell ML. Age-and sex-related reference ranges of alanine aminotransferase levels in children: European Paediatric HCV Network. J. Pediatr. Gastroenterol. Nutr. 49, 71-77 (2009).
19. Blumenthal S, Epps RP, Heavenrich R et al. Report of the task force on blood pressure control in children. Pediatrics 59(5 Suppl. 2), I-II, 797-820 (1977). (Pubitemid 8103605)
20. Moffatt MF, Gut IG, Demenais F et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363(13), 1211-1221 (2010).
21. Levine N. Pediatric inflammatory bowel disease: is it different? Dig. Dis. 27, 212-214 (2009).
22. Wagner-Weiner L. Pediatric rheumatology for the adult rheumatologist. J. Clin. Rheumatol. 14, 109-119 (2008). (Pubitemid 351519200)
23. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, healthcare use, and mortality: United States, 2005-2009. Natl Health Stat. Report 32, 1-14 (2011).
24. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am. J. Respir. Crit. Care Med. 159, 179-187 (1999). (Pubitemid 29036522)
25. Stanojevic S, Wade A, Stocks J et al. Reference ranges for spirometry across all ages: a new approach. Am. J. Respir. Crit. Care Med. 177, 253-260 (2008). (Pubitemid 351198367)
26. Barnes MG, Grom AA, Thompson SD et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60, 2102-2112 (2009).
27. Knowlton N, Jiang K, Frank MB et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum. 60(3), 892-900 (2009).
28. Piana C, Surh L, Furst-Recktenwald S et al. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases. J. Clin. Pharmacol. doi:10.1177/0091270011401619 (2011) (Epub ahead of print).
29. Burgner D, Davila S, Breunis WB et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet. 5(1), e1000319 (2009).
30. Tsai FJ, Lee YC, Chang JS et al. Identification of novel susceptibility loci for Kawasaki disease in a Han Chinese population by a genome-wide association study. PLoS One 6(2), e16853 (2011).
31. Nguyen LB, Diskin SJ, Capasso M et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci. PLoS Genet. 7(3), e1002026 (2011).
32. Glessner JT, Bradfield JP, Wang K et al. A genome-wide study reveals copy number variants exclusive to childhood obesity cases. Am. J. Hum. Genet. 87(5), 661-666 (2010).
33. Hens K, Cassiman JJ, Nys H, Dierickx K. Children, biobanks and the scope of parental consent. Eur. J. Hum. Genet. 19, 735-739 (2011).
34. Moran C, Thornburg CD, Barfield RC. Ethical considerations for pharmacogenomic testing in pediatric clinical care and research. Pharmacogenomics 12, 889-895 (2011).
35. Hinks A, Barton A, Shephard N et al. Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. Arthritis Rheum. 60(1), 258-263 (2009).
36. Moffatt MF, Kabesch M, Liang L et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448(7152), 470-473 (2007). (Pubitemid 47123521)
37. Kugathasan S, Baldassano RN, Bradfield JP et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat. Genet. 40, 1211-1215 (2008).
38. Bouzigon E, Corda E, Aschard H et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N. Engl. J. Med. 359, 1985-1994 (2008).
39. Halapi E, Gudbjartsson DF, Jonsdottir GM et al. A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur. J. Hum. Genet. 18(8), 902-908 (2010).
40. Leung TF, Sy HY, Ng MCY et al. Asthma and atopy are associated with chromosome 17q21 markers in Chinese children. Allergy 64(4), 621-628 (2009).
41. Stevens JC, Marsh SA, Zaya MJ et al. Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36, 1587-1593 (2008).
42. Blake MJ, Gaedigk A, Pearce RE et al. Ontogeny of dextromethorphan O-and N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510-516 (2007). (Pubitemid 46452306)
43. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr. Anaesth. 21, 266-273 (2011).
44. Leeder JS, Kearns GL, Spielberg SP, Van Den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol. 50, 1377-1387 (2010).
45. De Wildt SN, Ito S, Koren G. Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov. Today 14, 6-15 (2009).
46. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci. 30(7), 375-386 (2009).
47. Nowak-Gottl U, Dietrich K, Schaffranek D et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 116(26), 6101-6105 (2010).
48. Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 94(9), 3007-3014 (1999). (Pubitemid 29512704)
49. Takahashi H, Ishikawa S, Nomoto S et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther. 68(5), 541-555 (2000).
50. Monagle P. Anticoagulation in the young. Heart 90(7), 808-812 (2004). (Pubitemid 38821078)
51. Payne JH. Aspects of anticoagulation in children. Br. J. Haematol. 150(3), 259-277 (2010).
52. Koukouritaki SB, Manro JR, Marsh SA et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308(3), 965-974 (2004). (Pubitemid 38263972)
53. Ward RM, Kearns GL, Tammara B et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J. Clin. Pharmacol. 51(6), 876-887 (2011).
54. Ward RM, Tammara B, Sullivan SE et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur. J. Clin. Pharmacol. 66(6), 555-561 (2010).
55. Li JS, Yow E, Berezny KY et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation 117(4), 553-559 (2008).
56. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
57. Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14(7), 429-440 (2004). (Pubitemid 38971233)
58. Hedman M, Antikainen M, Holmberg C et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol. 61(6), 706-715 (2006). (Pubitemid 43794798)
59. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31(2), 390-392 (2004). (Pubitemid 38160763)
60. Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr. Drugs 13(3), 161-173 (2011).
61. Giannini EH, Brewer EJ, Kuzmina N et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N. Engl. J. Med. 326(16), 1043-1049 (1992).
62. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260(17), 9720-9726 (1985). (Pubitemid 15013030)
63. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76(3), 907-912 (1985). (Pubitemid 16225582)
64. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J. Rheumatol. 22(5), 844-849 (1995).
65. Ravelli A, Di Fuccia G, Molinaro M et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J. Rheumatol. 20(9), 1573-1577 (1993). (Pubitemid 24027335)
66. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004). (Pubitemid 39209513)
67. Becker ML, Gaedigk R, Van Haandel L et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 63(1), 276-285 (2011).
68. Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 44(1), 74-79 (2005). (Pubitemid 40124335)
69. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92(6), 2675-2682 (1993). (Pubitemid 24006532)
70. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin. Pharmacol. Ther. 46(5), 510-520 (1989). (Pubitemid 20009867)
71. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327(26), 1832-1835 (1992). (Pubitemid 23003073)
72. Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am. J. Cardiol. 106(4), 517-527 (2010).
73. Kerr MA, Livingstone B, Bates CJ et al. Folate, related B vitamins, and homocysteine in childhood and adolescence: potential implications for disease risk in later life. Pediatrics 123(2), 627-635 (2009).
74. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Cough and cold medication use by US children, 1999-2006: results from the Slone survey. Pediatrics 122(2), e323-329 (2008).
75. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J. Allergy Clin. Immunol. 86(4 Pt 1), 540-547 (1990). (Pubitemid 20372514)
76. Van Steekelenburg J, Clement PA, Beel MH. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 57(4), 346-350 (2002). (Pubitemid 34280664)
77. Simons F. Advances in H1-antihistamines. N. Engl. J. Med. 351, 2203-2217 (2004).
78. Watson WT, Simons KJ, Chen XY, Simons FE. Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 84(4 Pt 1), 457-464 (1989). (Pubitemid 19266741)
79. Eun HC. Evaluation of skin blood flow by laser Doppler flowmetry. Clin. Dermatol. 13(4), 337-347 (1995).
80. Magerl W, Westerman RA, Mohner B, Handwerker HO. Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. J. Invest. Dermatol. 94, 347-352 (1990). (Pubitemid 20061645)
81. Heyer G, Hornstein OP, Handwerker HO. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J. Invest. Dermat. 93, 492-496 (1989). (Pubitemid 19225494)
82. Jones BL, Abdel-Rahman SM, Simon SD, Kearns GL, Neville KA. Assessment of histamine pharmacodynamics by microvasculature response of histamine using histamine iontophoresis laser Doppler flowimetry. J. Clin. Pharmacol. 49(5), 600-605 (2009).
83. Pediatric Pathology (2nd Edition). Stocker JT, Dehner LP (Eds). Lippincott, Williams & Wilkins, Philadelphia, PA, USA (2001).
84. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transplant. 12, 1481-1493 (2005). (Pubitemid 43072624)
85. Centers for Disease Control and Prevention. Growth Charts, September 2010. www.cdc.gov/growthcharts (Accessed 2 August 2011)
86. Therapeutics for Rare & Neglected Diseases (TRND) program at NIH. http://trnd.nih.gov/(Accessed 15 August 2011)
87. Coumadin Official US FDA information, side effects and uses. www.drugs.com/pro/coumadin.html